LOGIN
Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects
September 2018
Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
Clin Ther. 2007 Sep;29(9):2068-79Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Sixty-six patients from the UK with multiple sclerosis (MS) were enrolled in an initial 5-week, placebo-controlled RCT investigating the use of an oral-mucosal THC/CBD spray (Sativex). This study is an uncontrolled, open-label extension of the initial RCT, where all patients completing the initial RCT (n=64) were eligible to continue on the THC/CBD oral spray, and followed for 2-years. Sixty-three...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.